Skip to main content
. 2006 Dec;2(4):360–374.

Table 5.

TRIAL I. Monthly changes in values of individual symptoms determined according to Kupperman’s Menopausal Index (KMI) recorded between Admission (A), and at three monthly sampling points (Month Model)a with one month Placebo (P) followed by two months Maca-GO (M) contrast according to the sequence APMM (at n = 55) applied in Trial I

Code# Symptom in KMI Admission A After 1m P After 1m M After 2m M ± SED P Placebo Maca-GO ± SEDb Pc
K-1   Hot flushes 3.94 3.17 2.16 1.64 0.580 0.002 1.761 0.651 0.152 <0.001
K-2   Excessive sweating 2.41 1.24 1.11 0.85 0.276 <0.001 1.391 0.673 0.162 <0.001
K-3   Interrupted sleep 1.98 1.15 0.75 0.78 0.267 <0.001 1.196 0.605 0.144 <0.001
K-4   Nervousness 2.63 1.63 1.18 0.61 0.237 <0.001 1.630 0.802 0.145 <0.001
K-5   Depression 1.24 0.61 0.45 0.46 0.197 <0.001 0.826 0.619 0.160 0.198
K-6   Losing body balance 0.87 0.39 0.32 0.32 0.186 0.006 0.696 0.395 0.125 0.017
K-7   General weakness 1.24 0.72 0.68 0.56 0.201 0.011 1.239 0.874 0.161 0.025
K-8   Joint pain 1.02 0.65 0.70 0.69 0.208 0.001 1.000 0.719 0.158 0.079
K-9   Headaches 1.20 0.61 0.45 0.34 0.188 0.009 0.717 0.452 0.132 0.047
K-10   Heart palpitations 1.02 0.46 0.32 0.22 0.185 <0.001 0.543 0.336 0.131 0.116
K-11   Numbness hands & legs 0.57 0.39 0.20 0.20 0.190 <0.001 0.543 0.336 0.135 0.126
  Total value for  KMI symptoms 26.61 22.04 12.83 7.52 1.13 <0.001 22.04 10.170 1.408 <0.001
a

For explanation see Table 1;

b

SED, Standard error of differences;

c

P, Probabilities of significance. ns, not significant at P>0.05; P<0.05, significance at 5% probability level; P<0.01, significance at 1% probability level; P<0.001, significance at 0.1% probability level. Scoring index: 0, symptom not experienced; 1, occasionally; 2, often; 3, very often. Kupperman’s Indexing Factors: K-1, ×4; K-2 to K-5, ×2; the remaining, ×1.